Do analysts recommend FTLF or VIRI?

FitLife Brands presently has a consensus price target of $21.50, suggesting a potential upside of 96.17%. Given FitLife Brands' stronger consensus rating and higher possible upside, equities analysts clearly believe FitLife Brands is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FitLife Brands 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend VIRI or ONCY?

Oncolytics Biotech has a consensus price target of $8.50, indicating a potential upside of 849.72%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oncolytics Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has stronger valuation & earnings, VIRI or ONCY?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A Oncolytics Biotech N/A N/A -$28.76M -$0.31 N/A

Is VIRI or ONCY more profitable?

Virios Therapeutics' return on equity of -130.33% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% Oncolytics Biotech N/A -2,185.97% -321.54%

Do analysts rate ANIX or VIRI?

Anixa Biosciences presently has a consensus price target of $8.50, indicating a potential upside of 142.86%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Anixa Biosciences is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anixa Biosciences 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ANIX or VIRI more profitable?

Anixa Biosciences' return on equity of -71.12% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -71.12% -62.88% Virios Therapeutics N/A -130.33% -115.00%

Do analysts recommend VIRI or BMEA?

Biomea Fusion has a consensus price target of $8.50, suggesting a potential upside of 577.29%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Biomea Fusion 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has better valuation and earnings, VIRI or BMEA?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A Biomea Fusion N/A N/A -$61.80M -$0.68 N/A

Is VIRI or BMEA more profitable?

Virios Therapeutics' return on equity of -130.33% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% Biomea Fusion N/A -265.37% -103.96%

Virios Therapeutics (VIRI) Competitors

$1.43 +0.05 (+3.62%)

As of 07/14/2026

Compare

VIRI vs. VRCA, FTLF, ONCY, ANIX, and BMEA

Should you buy Virios Therapeutics stock or one of its competitors? MarketBeat compares Virios Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Virios Therapeutics include Verrica Pharmaceuticals (VRCA), FitLife Brands (FTLF), Oncolytics Biotech (ONCY), Anixa Biosciences (ANIX), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry.

How does Virios Therapeutics compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

In the previous week, Verrica Pharmaceuticals had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 1 mentions for Verrica Pharmaceuticals and 0 mentions for Virios Therapeutics. Verrica Pharmaceuticals' average media sentiment score of 1.87 beat Virios Therapeutics' score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Verrica Pharmaceuticals	Very Positive
Virios Therapeutics	Neutral

Virios Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Virios Therapeutics' return on equity of -130.33% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Virios Therapeutics	N/A	-130.33%	-115.00%

Verrica Pharmaceuticals currently has a consensus target price of $14.50, indicating a potential upside of 140.86%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Verrica Pharmaceuticals is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Virios Therapeutics has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Virios Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.91	-$17.89M	-$1.03	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Verrica Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

Summary

Verrica Pharmaceuticals beats Virios Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Virios Therapeutics compare to FitLife Brands?

FitLife Brands (NASDAQ:FTLF) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

FitLife Brands has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

FitLife Brands presently has a consensus price target of $21.50, suggesting a potential upside of 96.17%. Given FitLife Brands' stronger consensus rating and higher possible upside, equities analysts clearly believe FitLife Brands is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, FitLife Brands had 3 more articles in the media than Virios Therapeutics. MarketBeat recorded 3 mentions for FitLife Brands and 0 mentions for Virios Therapeutics. FitLife Brands' average media sentiment score of 1.60 beat Virios Therapeutics' score of 0.00 indicating that FitLife Brands is being referred to more favorably in the media.

Company	Overall Sentiment
FitLife Brands	Very Positive
Virios Therapeutics	Neutral

FitLife Brands has higher revenue and earnings than Virios Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.26	$6.33M	$0.60	18.27
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

2.3% of FitLife Brands shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 61.7% of FitLife Brands shares are held by insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

FitLife Brands has a net margin of 6.64% compared to Virios Therapeutics' net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
Virios Therapeutics	N/A	-130.33%	-115.00%

Summary

FitLife Brands beats Virios Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Virios Therapeutics compare to Oncolytics Biotech?

Virios Therapeutics (NASDAQ:VIRI) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

Virios Therapeutics' return on equity of -130.33% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Oncolytics Biotech	N/A	-2,185.97%	-321.54%

In the previous week, Oncolytics Biotech had 4 more articles in the media than Virios Therapeutics. MarketBeat recorded 4 mentions for Oncolytics Biotech and 0 mentions for Virios Therapeutics. Oncolytics Biotech's average media sentiment score of 1.16 beat Virios Therapeutics' score of 0.00 indicating that Oncolytics Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Virios Therapeutics	Neutral
Oncolytics Biotech	Positive

Oncolytics Biotech has a consensus price target of $8.50, indicating a potential upside of 849.72%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Oncolytics Biotech is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Virios Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A

9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, Oncolytics Biotech has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Summary

Virios Therapeutics and Oncolytics Biotech tied by winning 7 of the 14 factors compared between the two stocks.

How does Virios Therapeutics compare to Anixa Biosciences?

Anixa Biosciences (NASDAQ:ANIX) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Anixa Biosciences has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market.

Anixa Biosciences' return on equity of -71.12% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Virios Therapeutics	N/A	-130.33%	-115.00%

In the previous week, Anixa Biosciences had 6 more articles in the media than Virios Therapeutics. MarketBeat recorded 6 mentions for Anixa Biosciences and 0 mentions for Virios Therapeutics. Anixa Biosciences' average media sentiment score of 0.57 beat Virios Therapeutics' score of 0.00 indicating that Anixa Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Anixa Biosciences	Positive
Virios Therapeutics	Neutral

Virios Therapeutics has lower revenue, but higher earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Virios Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	567.00	-$10.93M	-$0.31	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Anixa Biosciences presently has a consensus price target of $8.50, indicating a potential upside of 142.86%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Anixa Biosciences is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Anixa Biosciences beats Virios Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Virios Therapeutics compare to Biomea Fusion?

Virios Therapeutics (NASDAQ:VIRI) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

In the previous week, Biomea Fusion had 6 more articles in the media than Virios Therapeutics. MarketBeat recorded 6 mentions for Biomea Fusion and 0 mentions for Virios Therapeutics. Biomea Fusion's average media sentiment score of 0.80 beat Virios Therapeutics' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Overall Sentiment
Virios Therapeutics	Neutral
Biomea Fusion	Positive

Virios Therapeutics' return on equity of -130.33% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Biomea Fusion	N/A	-265.37%	-103.96%

Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market.

9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by insiders. Comparatively, 10.6% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Virios Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

Biomea Fusion has a consensus price target of $8.50, suggesting a potential upside of 577.29%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Biomea Fusion beats Virios Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Virios Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIRI vs. The Competition

Export

Metric	Virios Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$27.54M	$934.40M	$6.79B	$12.62B
Dividend Yield	N/A	4.84%	2.68%	8.43%
P/E Ratio	-5.30	1.55	27.04	24.39
Price / Sales	N/A	116.68	521.74	91.34
Price / Cash	N/A	20.06	48.59	59.39
Price / Book	7.15	8.59	10.83	6.31
Net Income	-$5.30M	-$3.40M	$3.59B	$331.45M
7 Day Performance	-0.69%	-1.75%	-1.30%	0.26%
1 Month Performance	-7.14%	-0.85%	2.97%	-0.64%
1 Year Performance	-71.85%	35.18%	28.58%	20.24%

Virios Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIRI Virios Therapeutics	N/A	$1.43 +3.6%	N/A	-71.0%	$27.54M	N/A	N/A	5
VRCA Verrica Pharmaceuticals	3.2201 of 5 stars	$6.07 -1.0%	$14.50 +138.9%	-27.2%	$105.31M	$35.58M	N/A	40	Positive News
FTLF FitLife Brands	4.6181 of 5 stars	$11.08 -1.0%	$21.50 +94.0%	-15.1%	$105.09M	$81.46M	18.34	20	News Coverage Positive News Short Interest Decrease
ONCY Oncolytics Biotech	3.2338 of 5 stars	$0.86 -2.8%	$8.50 +893.2%	-24.3%	$105.06M	N/A	N/A	30	Positive News Analyst Upgrade
ANIX Anixa Biosciences	4.0736 of 5 stars	$2.96 -3.0%	$8.50 +187.2%	-0.3%	$103.77M	$210K	N/A	5	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIRI) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virios Therapeutics (VIRI) Competitors

VIRI vs. VRCA, FTLF, ONCY, ANIX, and BMEA

How does Virios Therapeutics compare to Verrica Pharmaceuticals?

Summary

How does Virios Therapeutics compare to FitLife Brands?

Summary

How does Virios Therapeutics compare to Oncolytics Biotech?

Summary

How does Virios Therapeutics compare to Anixa Biosciences?

Summary

How does Virios Therapeutics compare to Biomea Fusion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIRI vs. The Competition

Virios Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virios Therapeutics (VIRI) Competitors

VIRI vs. VRCA, FTLF, ONCY, ANIX, and BMEA

How does Virios Therapeutics compare to Verrica Pharmaceuticals?

Does the media prefer VRCA or VIRI?

Is VRCA or VIRI more profitable?

Do analysts recommend VRCA or VIRI?

Do institutionals and insiders have more ownership in VRCA or VIRI?

Which has preferable valuation and earnings, VRCA or VIRI?

Which has more volatility and risk, VRCA or VIRI?

Summary

How does Virios Therapeutics compare to FitLife Brands?

Which has more volatility & risk, FTLF or VIRI?

Do analysts recommend FTLF or VIRI?

Does the media prefer FTLF or VIRI?

Which has better valuation & earnings, FTLF or VIRI?

Do institutionals & insiders hold more shares of FTLF or VIRI?

Is FTLF or VIRI more profitable?

Summary

How does Virios Therapeutics compare to Oncolytics Biotech?

Is VIRI or ONCY more profitable?

Does the media prefer VIRI or ONCY?

Do analysts recommend VIRI or ONCY?

Which has stronger valuation & earnings, VIRI or ONCY?

Do institutionals and insiders believe in VIRI or ONCY?

Which has more volatility and risk, VIRI or ONCY?

Summary

How does Virios Therapeutics compare to Anixa Biosciences?

Which has more risk and volatility, ANIX or VIRI?

Is ANIX or VIRI more profitable?

Does the media refer more to ANIX or VIRI?

Which has better earnings & valuation, ANIX or VIRI?

Do institutionals & insiders have more ownership in ANIX or VIRI?

Do analysts rate ANIX or VIRI?

Summary

How does Virios Therapeutics compare to Biomea Fusion?

Does the media favor VIRI or BMEA?

Is VIRI or BMEA more profitable?

Which has more volatility & risk, VIRI or BMEA?

Do insiders and institutionals hold more shares of VIRI or BMEA?

Which has better valuation and earnings, VIRI or BMEA?

Do analysts recommend VIRI or BMEA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIRI vs. The Competition

Virios Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools